Related Experiment Videos
Malignant fibrous histiocytoma: histomorphological pattern or tumor type
1Institute of Pathology, Städt Krankenhaus München-Harlaching, München, Germany.
Pathology, Research and Practice
|August 1, 1996
Summary
Malignant fibrous histiocytoma (MFH) was often a diagnosis for unclassified tumors. Immunohistochemistry reclassified many MFH cases, but some primitive mesenchymal tumors still fit strict MFH criteria, making the diagnosis rarer but still valid.
Area of Science:
- Oncology
- Pathology
- Immunohistochemistry
Background:
- Malignant fibrous histiocytoma (MFH) has historically been a diagnostic category for poorly understood tumors.
- Immunohistochemistry has provided new insights into tumor cell differentiation.
Purpose of the Study:
- To re-evaluate the diagnostic criteria for MFH.
- To determine the utility of immunohistochemistry in classifying tumors previously diagnosed as MFH.
Main Methods:
- Utilized immunohistochemistry to analyze cellular differentiation in neoplastic proliferations.
- Applied strict histological and immunohistochemical criteria for MFH diagnosis.
Main Results:
- Immunohistochemistry identified unexpected antigen expression (e.g., cytokeratins) in some MFH cases.
- Many tumors previously diagnosed as MFH were reclassified as leiomyosarcoma, melanoma, or anaplastic carcinoma.
- A subset of sarcomas lacking specific differentiation markers, with primitive mesenchymal/fibroblastic cells and a storiform pattern, still meet MFH criteria.
Conclusions:
- The diagnosis of MFH is becoming rarer due to more precise classification methods.
- MFH remains a valid diagnosis for specific mesenchymal tumors lacking clear differentiation markers.